Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer

Clinical Colorectal Cancer

Volumn 3, Issue 4, 2004, Pages 225-234

  Zhu, Andrew X ^a   Puchalski, Thomas A ^a   Stanton Jr , Vincent P ^b   Ryan, David P ^a   Clark, Jeffrey W ^a   Nesbitt, Steven ^b   Charlat, Olga ^b   Kelly, Patrick ^c   Kreconus, Elaine ^a   Chabner, Bruce A ^a   Supko, Jeffrey G ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Variagenics Inc   (United States)

^c UNIVERSITY OF READING   (United Kingdom)

Author keywords

Catabolism; Clinical studies; Genotypes; Pharmacokinetics; Toxicity

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FOLINIC ACID; THYMIDYLATE SYNTHASE;

5' UNTRANSLATED REGION; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL OBSERVATION; COHORT ANALYSIS; COLORECTAL CANCER; CONSTIPATION; CONTROLLED STUDY; CORRELATION COEFFICIENT; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG CLEARANCE; DRUG ELIMINATION; DRUG ERUPTION; EYE TOXICITY; FEMALE; GASTROINTESTINAL TOXICITY; GENE FUNCTION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPERGLYCEMIA; INFECTIOUS COMPLICATION; LEUKOPENIA; LIVER TOXICITY; LUNG TOXICITY; MALE; METABOLIC DISORDER; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NUCLEOTIDE SEQUENCE; PAIN; PHARMACOGENETICS; PLASMA HALF LIFE; SKIN TOXICITY; STOMATITIS;

EID: 11144357119     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2004.n.003     Document Type: Article

References (36)

1. Jemal A, Tiwari R, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54:8-29.
2. Grem JL. Systemic treatment options in advanced colorectal cancer: Perspectives on combination 5-fluorouracil plus leucovorin. Semin Oncol 1997; 24:S18-8-S18-18.
3. Buroker TR, O'Connell MJ, Wieand HS, et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994; 12:14-20.
4. Macdonald JS. Toxicity of 5-fluorouracil. Oncology (Huntingt) 1999; 13:33-34.
5. Sargent DJ, Niedzwiecki D, O'Connell MJ, et al. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 2001; 345:144-146.
6. Stein BN, Petrelli NJ, Douglas HO, et al. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 1995; 75:11-17.
7. Milano G, Etienne MC, Cassuto-Viguier E, et al. Influence of sex and age on fluorouracil clearance. J Clin Oncol 1992; 10:1171-1175.
8. van Groeningen CJ. Pinedo HM, Heddes J, et al. Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. Cancer Res 1988; 48:6956-6961.
9. Terret C, Erdociain E, Guimbaud R, et al. Dose and time dependencies of 5-fluorouracil pharmacokinetics. Clin Pharmacol Ther 2000; 68:270-279.
10. Gabrielsson J, Weiner, D. Pharmacokinetic/Pharmacodynamic Data Analysis. Stockholm: Swedish Pharmaceutical Press, 1994.
11. Gamelin E, Bouil AL, Boisdron-Celle M, et al. Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks. combined with 5-fluorouracil in colorectal cancer patients. Clin Cancer Res 1997; 3:891-899.
12. Diasio RB, Beavers TL, Carpenter JT. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 1988; 81:47-51.
13. Raida M, Schwabe W, Hausler P, et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5FU)- related toxicity compared with controls. Clin Cancer Res 2001; 7:2832-2839.
14. Hartl DL, Clark AG. Principles of Population Genetics; 3rd ed. Sinauer Associates, Sunderland, MA, 1997.
15. Lu Z, Zhang R, Diasio RB. Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy. Clin Pharmacol Ther 1995; 58: 512-522.
16. Collie-Duguid ES, Etienne MC, Milano G, et al. Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics 2000; 10:217-223.
17. Pullarkat ST, Stoehlmacher J, Ghaderi V, et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001; 1:65-70.
18. Marsh S, McKay JA, Cassidy J, et al. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol 2001; 19:383-386.
19. Iacopetta B, Grieu F, Joseph D, et al. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 2001; 85:827-830.
20. Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria: Version 2.0. an improved reference for grading the acute effects of cancer treatment: Impact on radiotherapy. Int J Radiat Oncol Biol Phys 2000; 47:13-47.
21. Ackland SP, Garg MB, Dunstan RH. Simultaneous determination of dihydrofluorouracil and 5-fluorouracil in plasma by high-performance liquid chromatography. Anal Biochem 1997; 246:79-85.
22. Supko JG, Garcia-Carbonero R, Puchalski TA, et al. Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs. Cancer Chemother Pharmacol 2001; 48:202-208.
23. Gibaldi M, Perrier D. Pharmacokinetics, 2nd ed. Marcel Dekker, New York, NY, 1982; 84-109; 409-416.
24. Mizuta E, Tsubotani A. Preparation of mean drug concentration-time curves in plasma. A study on the frequency distribution of pharmacokinetic parameters. Chem Pharm Bull (Tokyo) 1985; 33:1620-1632.
25. Lacey LF, Keene ON, Pritchard JF, et al. Common noncompartmental pharmacokinetic variables: Are they normally or log-normally distributed? J Biopharm Stat 1997; 7:171-178.
26. Lam FC, Hung TC, Perrier DG. Estimation of variance for harmonic mean half-lives. J Pharm Sci 1985; 74:229-231.
27. Ten Asbroek AL, Olsen J, Housman D, et al. Genetic variation in mRNA coding sequences of highly conserved genes. Physiol Genomics 2001; 5:113-118.
28. Chomczynski P. A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques 1993; 15:532-534, 536-537.
29. Nickerson DA, Tobe VO, Taylor SL. PolyPhred: Automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing. Nucleic Acids Res 1997; 25:2745-2751.
30. van Kuilenburg AB, Dobritzsch D, Meinsma R, et al. Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure. Biochem J 2002; 364:157-163.
31. McLeod HL, Collie-Duguid ES, Vreken P, et al. Nomenclature for human DPYD alleles. Pharmacogenetics 1998; 8:455-459.
32. Port RE, Daniel B, Ding RW, et al. Relative importance of dose, body surface area, sex, and age for 5-fluorouracil clearance. Oncology 1991; 48:277-281.
33. Moore MJ, Erlichman C, Thiessen JJ, et al. Variability in the pharmacokinetics of cyclophosphamide, methotrexate and 5-fluorouracil in women receiving adjuvant treatment for breast cancer. Cancer Chemother Pharmacol 1994; 33:472-476.
34. Larsson PA, Glimelius B, Jeppsson B, et al. A pharmacokinetic study of 5-FU/leucovorin and alpha-interferon in advanced cancer. Acta Oncol 2000; 39:59-63.
35. van Kuilenburg AB, Haasjes J, Richel DJ, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: Identification of new mutations in the DPD gene. Clin Cancer Res 2000; 6:4705-4712.
36. Johnson MR, Wang K, Diasio RB. Profound dihydropyrimidine dehydgrogenase deficiency resulting from a novel compound heterozygote genotype. Clin Cancer Res 2002; 8:768-774.